Chester County News and Community Website
Immunome (NASDAQ: IMNM), headquartered in Exton, PA, is a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Immunome’s proprietary discovery platform identifies novel therapeutic antibodies and their targets by leveraging highly educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease. For more information about the company, visit http://immunome.com.
EXTON, PA — Immunome, Inc., a Chester County-based biotechnology company, recently announced that their cocktail (IMM-BCP-01) retained activity against the BA.4/5 and BA.2.12.1 subvariants in pseudovirus testing. IMM-BCP-01 is currently …
Chester County-based Biotechnology Company Provides Hope in Fight Against COVID-19 Read More
EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) recently announced the first patient has been enrolled in a clinical trial of IMM-BCP-01, a three-antibody cocktail for the treatment of SARS-CoV-2 (COVID-19). …
Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19 Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) recently announced updates to the ongoing development of its lead oncology program, IMM-ONC-01, a novel immuno-oncology agent that inhibits IL-38, an immunosuppressive cytokine.
Immunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38 Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) recently reported financial results for the first quarter ended March 31, 2022, and provided a corporate update.
Immunome Reports First Quarter 2022 Financial Results Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) recently reported financial results for the fourth quarter ended December 31, 2021, and provided a corporate update.
Immunome Reports Fourth Quarter, Full Year 2021 Financial Results Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) announced a recent update regarding its Investigational New Drug (IND) submission for IMM-BCP-01, a three-antibody cocktail, for the treatment of SARS-CoV-2 (COVID-19).
Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19 Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) announced that it recently submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for IMM-BCP-01, a three-antibody …
Immunome Announces Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19 Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.
Immunome Reports Third Quarter 2021 Financial Results Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) announced that it recently submitted to bioRxiv a preprint of a manuscript regarding preclinical research of the company’s SARS-CoV-2 antibody cocktail, IMM-BCP-01. The …
Immunome Announces Submission for Publication of Pre-clinical Research for SARS-CoV-2 Treatment and Prophylaxis Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) announced that Purnanand Sarma, Ph.D., Immunome’s President and CEO, will present at the Cantor Global Healthcare Conference on Wednesday, September 29, 2021, at …
Immunome to Present at the Cantor Global Healthcare Conference Read More